Cost-effectiveness of psoriasis therapy with etanercept in Germany
ثبت نشده
چکیده
Study population The study population comprised a hypothetical cohort of patients with moderate-to-severe psoriasis. Three sub-groups of patients were considered on the basis of disease severity, as represented by two scores, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). The three sub-groups were PASI and DLQI greater than 10, PASI and DLQI greater than 15, and PASI and DLQI greater than 20.
منابع مشابه
Cost-effectiveness of psoriasis therapy with etanercept in Germany.
BACKGROUND We estimated the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison to non-systemic therapy in Germany. PATIENTS AND METHODS We performed a cost-utility analysis using the endpoint costs per quality-adjusted life year gained (costs/QALY). For this purpose, we adapted a UK-based Markov model by means of ...
متن کاملA cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
INTRODUCTION Biologic therapies have proven efficacious for patients with moderate-to-severe psoriasis. However, their economic value compared with standard of care in Italy has not been explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic therapy in Italy. METHODS...
متن کاملLong-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
INTRODUCTION Pharmacoeconomic studies examining the cost-effectiveness of biological agents to treat moderate-to-severe psoriasis in real-life clinical practice are scarce. The aim of this study was to assess the efficiency, in terms of incremental cost-effectiveness, of etanercept and adalimumab in a real clinical setting. METHODS Direct and indirect costs were assessed from a Spanish societ...
متن کاملEconomic evaluation of etanercept in the management of chronic plaque psoriasis.
BACKGROUND The National Institute for Health and Clinical Excellence has recommended that etanercept 25 mg twice weekly (biw) be used in adults with severe plaque psoriasis. However, its economic model did not consider the alternative licensed regimen of etanercept 50 mg biw. OBJECTIVES To assess the cost-effectiveness of etanercept 50 mg biw for the treatment of chronic plaque psoriasis, and...
متن کاملEconomic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
BACKGROUND New biologic therapies are available for moderate to severe psoriasis. OBJECTIVE To determine the most cost-effective sequence of biologic treatments. METHODS Through modeling of the clinical pathway of biologic agents, adalimumab, alefacept, efalizumab, etanercept, and infliximab, the costs and benefits (quality-adjusted life-years [QALYs]) were determined. A decision rule deter...
متن کامل